Citations

Clear

4437 citation(s) found for "Lee, Mi Ji".

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Clinician Counseling and Patient Storage and Disposal Practices for Opioids Prescribed for Acute Pain: A Multicenter Prospective Cohort Study
Taherifard, Erfan , Ahadpour, Mitra , Chang, Nancy, Allen, Summer V. , Elie, Marie‐Carmelle , Fillmore, W. Jonathan , Gilbert, Gregg H. , Heckmann, Rebekah, Koussis, Patricia, Lee, Christine, Lipkind, Heather S. , Mallama, Celeste A. , Meyer, Tamra E. , Nuckols, Teryl K. , Ritchie, Jessica , Pacanowski, Michael , Page, David B. , Soukup, Mat, Tamang, Stephen, Torbati, Sam , Wallace, Doug, Walter, Lauren A. , Zhao, Yueqin, Shah, Nilay D. , Ross, Joseph S. , Jeffery, Molly Moore

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.26367278 Get It

ABSTRACT BACKGROUND Opioids prescribed for acute pain frequently remain unused, creating opportunities for unintended use, accidental ingestion, or diversion. Little is known about counseling patients receive from prescribers or pharmacists on storage and disposal of opioids. OBJECTIVE To characterize clinician counseling on opioid disposal and patient-reported storage, use, and disposal practices among opioid-naïve patients prescribed opioids for acute pain. DESIGN Multicenter prospective cohort study with participant recruitment between September 2020 and March 2023. PARTICIPANTS Opioid-naïve patients prescribed opioids for acute pain in emergency departments, primary care or urgent care clinics, inpatient settings, and dental practices. MAIN MEASURES Patient-reported receipt of counseling on the importance of opioid disposal and appropriate disposal methods; opioid storage practices; use and disposition of prescribed opioids; disposal methods; and reasons for keeping or disposing of leftover opioids. KEY RESULTS Among 1708 participants, the median age was 38 years (IQR, 28-52); most were recruited from emergency departments (n=915; 53.6%) and primary care or urgent care clinics (n=307; 18.0%). Among 1233 participants who answered the question on counseling about the importance of opioid disposal, 811 (65.8%) reported receiving no counseling. Among 1220 participants who answered the question on counseling about appropriate disposal methods, 832 (68.2%) reported receiving no counseling. Among 812 participants who answered the question about storing opioids in a locked location, 610 (75.1%) reported never doing so. Among 929 participants providing information on opioid leftovers and disposition, 618 (66.5%) did not use all prescribed opioids. Among these 618 participants, 258 (42.8%) kept leftover opioids and 345 (57.2%) disposed of them. Among 256 participants who reported reasons for keeping leftover opioids, 159 (62.1%) wanted medication available for the same condition, 70 (27.3%) wanted medication available for a different condition, and 36 (14.1%) did not know how to properly dispose of the medication. CONCLUSIONS Among opioid-naïve patients prescribed opioids for acute pain, counseling about opioid disposal was uncommon, secure storage was infrequent, and leftover opioids were frequent, with many patients keeping leftover opioids for possible future use. These findings suggest opportunities to improve counseling on opioid storage and disposal and encourage safe disposal of unused opioids after acute pain treatment.
Agentic AI-Generated vs. Clinician-Authored Hospital Course Narratives for Cardiology Hospitalizations: A Blinded Physician Evaluation
Lee, Eunjung , Harmon, David , Holmes, Jason , Allman, Alexandra E. , Saey, Stephanie , Schlesinger, Reid P , Félix, Iuri Ferreira , Friedman, Paul A , Attia, Zachi I.

Mayo Clinic

Circulation: Population Health and Outcomes | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circoutcomes.126.014472 | PMID 42993583 Get It

Background: Discharge summaries are essential for safe transitions of care, but writing the hospital course narrative is time intensive. Large language models can generate plausible clinical narratives, yet prior approaches often rely on static inputs and remain vulnerable to omissions and factual inconsistencies. Methods: We developed an electronic health record (EHR)-integrated agentic artificial intelligence (AI) system that uses Gemini 2.5 Pro and Model Context Protocol tools to retrieve clinical notes, diagnostic reports, diagnoses, medications, and appointments on demand. In this retrospective, blinded, paired study, 50 inpatient cardiology encounters were randomly selected from admissions July 13 to 27, 2024, at Mayo Clinic, Rochester, Minnesota. Five physicians rated AI-generated and clinician-authored hospital course narratives for each encounter (250 ratings) on 0-to-10 scales for overall quality, clarity, completeness, accuracy, and readability and indicated a preference. The primary outcome was the paired difference in overall quality (linear mixed-effects model with crossed random intercepts for encounter and reviewer). Secondary domains were analyzed similarly with Bonferroni adjustment, and preference with a crossed random-effects logistic model. Results: Clinician-authored narratives were preferred in 132 ratings (52.8%) and AI-generated narratives in 118 (47.2%) (odds ratio for clinician-authored preference, 1.12; 95% CI, 0.71 to 1.78). Overall quality did not differ significantly (mean, 7.27 AI-generated versus 7.42 clinician-authored; difference, -0.15; 95% CI, -0.86 to 0.56; p=0.627). AI-generated narratives were rated higher for clarity (0.36; 95% CI, 0.07 to 0.65) and readability (0.72; 95% CI, 0.20 to 1.24) but lower for completeness (-0.84; 95% CI, -1.36 to -0.32) and accuracy (-0.35; 95% CI, -0.66 to -0.05). After Bonferroni correction, only lower completeness remained significant (adjusted p=0.012). Conclusions: Hospital course narratives generated by the EHR-integrated agentic AI system did not differ significantly from clinician-authored narratives in physician-rated overall quality or preference. Lower completeness supports continued clinician review before use in the medical record.
Reconstruction of a Vermilion and Non-vermilion Upper Lip Defect
An, Miranda B. , Lee, Jaeeun, Rotunda, Adam M.

Mayo Clinic

Dermatologic Surgery | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005443 | PMID 42975429 Get It

Cost comparison of the ShangRing device versus Mogen clamp for early infant male circumcision in Sub-Saharan Africa
Punjani, Nahid, Zhang, Tenny R. , Basourakos, Spyridon P. , Barone, Mark A. , Christensen, Alice , Kigozi, Godfrey, Goldstein, Marc, Li, Philip S. , Mushlin, Alvin I. , Stover, John , Lee, Richard K.

Mayo Clinic

PLOS One | October 13, 2026 | Volume: 21 | Issue: 10 | Pages: e0360356

10.1371/journal.pone.0360356 | PMID 42868147 Get It

Introduction The World Health Organization (WHO) endorses male circumcision as an effective human immunodeficiency virus (HIV) prevention intervention in settings where the expected impact is greatest, including Sub-Saharan Africa. Data on cost implications of early infant male circumcision (EIMC) are limited. The ShangRing (SR) is a WHO pre-qualified device for circumcision. We sought to perform a comprehensive cost assessment alongside a randomized controlled trial (RCT) of the SR versus the standard of care Mogen clamp (MoC) for EIMC to enable future scale-up towards a cost-effective HIV prevention strategy. Methods We collected resource utilization and economic data as part of an RCT of infants aged 0–60 days old undergoing EIMC in Kenya, Tanzania, and Uganda. Cost data for both the SR and MoC included baseline facility costs, direct costs, and indirect costs. The Decision Makers Program Planning Tool v1.0 was used to perform a direct cost comparison of these two devices. The Goals model was used to compare the costs of EIMC in 2023 using the present value of money to circumcise an adolescent male 15 years from now. Results A total of 1,378 infant males underwent circumcision, 689 via SR and 689 via MoC. The overall cost of a single EIMC in Kenya, Tanzania, and Uganda were 61.30 United States Dollars ($), $47.14, and $64.59 respectively for the SR, and $56.38, $50.43, and $58.57 respectively for the MoC. In Kenya, EIMC would be less expensive based on nominal present costs in 2023 compared to waiting for adolescent circumcision at age 15 years in 2038. This finding is reversed in Tanzania and Uganda. Conclusions The overall cost of EIMC via SR versus MoC is comparable in an RCT. With scale-up utilizing lower level personnel, the cost of SR may be further reduced. The SR is an attractive alternative for future EIMC initiatives in Sub-Saharan Africa to further reduce HIV burden.
Normative transcriptomic clues to thalamic developmental vulnerability in C9orf72-FTLD
So, Isis , Bouzigues, Arabella , Ferry-Bolder, Eve , Cullen, Eva , Foster, Phoebe H , Farley, Sophie , Convery, Rhian , Jiskoot, Lize C , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Bruffaerts, Rose , Bertoux, Maxime , Lebouvier, Thibaud , Solje, Eino , Xiong, Chengjie , Thompson, Alexander , Körtvélyessy, Peter , Otto, Markus , Uzelac, Zeljko , Illán-Gala, Ignacio , Gerhard, Alexander , Ducharme, Simon , Santana, Isabel , Masellis, Mario , Rowe, James B , Graff, Caroline , Moreno, Fermin , Synofzik, Matthis , Rademakers, Rosa , Kolander, Tyler , Boeve, Brad , Rosen, Howard J , Lee, Suzee E , Rohrer, Jonathan D , Andrews, Tallulah S , Finger, Elizabeth C.

Mayo Clinic

No container title available | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.09.26365172 | PMID 42999299 Get It

C9orf72 encodes a protein that is important for both typical neurodevelopment and homeostatic processes across the lifespan. Pathogenic C9orf72 repeat expansions constitute the most common genetic cause of frontotemporal lobar degeneration (FTLD). Collectively, preclinical models and clinical neuroimaging studies have observed smaller thalamic volumes in C9orf72-associated FTLD, including in asymptomatic young adult C9orf72 repeat expansion carriers across 18 to 30 years old, supportive of potential neurodevelopmental origins. However, it is unknown whether asymptomatic young adult C9orf72 expansion carriers demonstrate volume differences in specific thalamic nuclei, as reported in older asymptomatic carriers and symptomatic patients; if so, normative transcriptomic patterns could reveal relevant neurodevelopmental and/or FTLD-related neurodegenerative processes. This study investigated volumetric MRI differences of the thalamic nuclei in asymptomatic young adult C9orf72 expansion carriers compared to non-carriers, and examined spatial associations with normative thalamic transcriptomics from 8 weeks post-conception through middle age. Young adult C9orf72 expansion carriers (n=72) and non-carriers (n=48) were enrolled in the Frontotemporal Dementia Prevention Initiative across Europe, Canada, and the USA (ages: 18-30 years; sex: 57% female). Spatial associations between young adult thalamic nuclei volumes and normative transcriptomics from the Allen Human Brain Atlas were examined using complementary data-driven and hypothesis-driven approaches. Spatial expression patterns of transcripts of interest were characterized across prenatal and postnatal neurodevelopment using BrainSpan data. Smaller volumes of the pulvinar, mediodorsal, and lateral nuclei were observed in young adult C9orf72 expansion carriers compared to non-carriers. These nuclei showed higher normative expression of transcripts involved concurrently in neurodevelopmental and C9orf72-associated FTLD neurodegenerative processes (including lysosomal, autophagic, and small GTPase functions), and lower normative expression of CALB1, a marker of prenatal human thalamic development. Normative expression of CALB2 (another human thalamic development marker) yielded positive correlations with C9orf72 across prenatal development to adulthood. These findings identify candidate transcripts that may provide insight into the molecular architecture leading to smaller thalamic nuclei volumes in C9orf72-associated FTLD.
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe, Matthew M , Le-Rademacher, Jennifer G , Haffty, Bruce G , Hansen, Eric K , Wagner, Jamie L , Kong, Iwa , Whelan, Timothy J , Kour, Odum, Lee, Minji K , Ruddy, Kathryn J , Partridge, Ann H , Carey, Lisa A , Lustberg, Maryam , Chow, Selina , Stecklein, Shane Richard , Gaffney, David K , Khan, Atif J.

Mayo Clinic

Journal of Clinical Oncology | October 12, 2026 | Volume: 44 | Issue: 32 | Pages: 3128-3138

10.1200/jco-26-00474 | PMID 42863096 Get It

PURPOSE Patients with breast cancer requiring postmastectomy radiation therapy (PMRT) often desire breast reconstruction. Reconstructions can be adversely affected by PMRT, and fear of reconstruction complications has discouraged adoption of short-course radiation therapy used after lumpectomy. To fill the evidence gap, we conducted a noninferiority trial of hypofractionated versus conventional PMRT in patients undergoing breast reconstruction. The primary outcome was reconstruction complication rate, a composite of wound healing, readmission, capsular contracture, unplanned reoperation, and reconstruction failure. METHODS Women with unilateral invasive breast cancer with planned immediate or delayed reconstruction and PMRT were randomly assigned (1:1) to 50 Gy (25 fractions/5 weeks) or 42.56 Gy (16 fractions/3 weeks). This study was designed with a noninferiority margin of 10%, assuming a 2-year reconstruction complication rate of 25% with conventional PMRT. Randomization was stratified by immediate versus delayed and autologous versus implant-only reconstruction. RESULTS Between 2018 and 2021, 898 patients enrolled with a median follow-up of 3.9 years; 825 patients were evaluable for the primary end point. The 24-month reconstruction complication rates were 12.3% (52/422) with hypofractionated PMRT and 10.2% (41/403) with conventional PMRT, corresponding to an estimated difference of -2.1% (95% CI, -6.5 to 2.2). The complication rate was higher (regardless of arm) with implant-only versus autologous reconstruction (odds ratio = 1.65). There was no statistically significant difference in 36-month locoregional recurrence rates: 1.5% (95% CI, 0.7 to 3.2) with hypofractionated and 2.2% (95% CI, 1.1 to 4.3) with conventional PMRT. Acute and late toxicity rates were not statistically different. CONCLUSION A 16-fraction course of hypofractionated PMRT is safe and noninferior to conventional PMRT in women undergoing breast reconstruction after mastectomy.
Cholera toxin remodels intestinal immunity and suppresses systemic metabolism
Roginski, Ana Cristina , Godazgar, Mahdieh , Salgado, Caio Loureiro , Lahiri, Gourab , Woodrow, Cheyanne , Costa Lima, Bruna Genisa , Rodriguez-Castano, Gina Paola , Voth-Gaeddert, Lee , Silva, Henrique Borges da , Dietrich, Marcelo O. , Mana, Miyeko D , Florsheim, Esther Borges , Roginski, Ana C , Salgado, Caio L , Hartley McDermott, Thomas , Borges da Silva, Henrique , Florsheim, Esther

Mayo Clinic

No container title available | October 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.29.755509 | PMID 42926400 Get It

Cholera toxin (CTx) is a potent enterotoxin and widely used mucosal adjuvant, yet the acute host response to CTx itself, in the absence of a co-administered antigen, remains vague. In this study, we integrated physiological and metabolic phenotyping with intestinal transcriptomics, epithelial imaging, immune profiling, hepatic gene-expression analysis, and paired microbiome profiling to characterize the response to a single oral CTx exposure in mice. Within 24 h, CTx remodeled immune-cell composition in both epithelial and lamina propria compartments, with responses shaped by sex and genetic background. Recurrent changes included increased epithelial group 3 innate lymphoid cells, reduced lamina propria RORγt+ regulatory T cells, and decreased epithelial ILC1/NK cells in males of both strains. CTx also increased villus DCLK1+ tuft cells and reduced MUC2 immunoreactivity. Jejunal transcriptomics revealed induction of inflammatory defense, glycolytic, autophagy, and lipid-utilization programs together with suppression of proliferative and mitochondrial programs, consistent with coordinated stress adaptation. These local changes were accompanied by rapid restructuring of the fecal microbial community and by systemic hypometabolism, despite markedly different hypothermic responses across strains. CTx also elicited a selective hepatic stress and metabolic program, including conserved suppression of Cyp7a1 across sexes and strains. Together, these findings show that CTx alone rapidly reorganizes the intestinal immune, epithelial, metabolic, and microbial environment while suppressing whole-body metabolism. This work provides an integrated framework for understanding the acute host response to CTx and for interpreting its widespread use as a mucosal adjuvant.
Metabolic reprogramming of pathogenic CD4 + T helper cells attenuates inflammatory bowel disease in mice
Mishra, Shravan K , Abdelrahman, Leena M , Kim Lee, Hyun Se , Valenzuela-Pérez, Lucía , Manna, Dina Faeq , Abram, Tanner J , Ali, Lama Mohamed , Davidson, Heidi M , Hassan, Omar M , Faubion, William A. , Hirsova, Petra , Bamidele, Adebowale O

Mayo Clinic

Science Signaling | October 6, 2026 | Volume: 19 | Issue: 958 | Pages: No page available

10.1126/scisignal.aeb2392 | PMID 42837442 Get It

CD4 + effector T helper 1 (T H 1) cells drive inflammatory bowel disease (IBD). Here, we investigated how integrated signaling, metabolic, and epigenetic programs sustain their pathogenic persistence. We found that enforcing mitochondrial pyruvate metabolism with methyl pyruvate (MePyr) suppressed T H 1 cell effector function and induced the acquisition of a regulatory-like phenotype. MePyr suppressed the activity of glycogen synthase kinase 3β (GSK3β), promoting a metabolic shift from glycolysis toward oxidative phosphorylation (OXPHOS) and limiting the accumulation of intracellular acetyl-CoA. This metabolic reprogramming decreased histone H3 acetylation at genes encoding inflammatory cytokines, thereby decreasing T H 1 cell–associated gene expression. Restoration of inflammatory cytokine production by acetate supplementation or histone deacetylase inhibition established acetyl-CoA–dependent histone acetylation as a mechanistic link between metabolic flux and effector function. Conversely, the cytokine interleukin-21 enhanced T H 1 cell effector activity by promoting a GSK3β-dependent shift from OXPHOS to glycolysis. Single-cell transcriptomic analysis of Crohn’s disease tissue revealed enrichment of glycolytic gene programs in nonregulatory CD4 + T cells. Consistent with these findings, pharmacologic inhibition of GSK3β attenuated disease severity in a T cell–transfer mouse model of colitis. Together, these findings identify a GSK3β-dependent metabolic-epigenetic axis that sustains T H 1 cell pathogenicity and highlight GSK3β as a potential therapeutic target for IBD.
Updates in the diagnosis of interstitial lung disease: evolving concepts and terminology
Maule, Geran, Lee, Augustine, Ryu, Jay

Mayo Clinic

Expert Review of Respiratory Medicine | September 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-13

10.1080/17476348.2026.2736889 | PMID 42803636 Get It